Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
NCT05822609
Recruiting
The primary objective of this study is to determine the effects of semaglutide on kidney oxygenation and function in type 1 diabetes. The secondary objective is to determine the glycemic effects and safety of semaglutide in type 1 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +3 locations
Conditions: Diabetic Kidney Disease, Type 1 Diabetes
Register for Updates
A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
NCT03987451
Completed
Semaglutide is a medicine studied in patients with non-alcoholic steatohepatitis (NASH), as it may improve liver damage. Participants will either get semaglutide or placebo (a dummy medicine) - which treatment participants get is decided by chance. The study will last for about 61 weeks in total. Participants will have 10 clinic visits and 3 phone calls with the study doctor or staff during the study. Some of the clinic visits may be spread over more days. Participants will need to inject themse... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/28/2024
Locations: Arizona Liver Health, Chandler, Arizona +37 locations
Conditions: Non-alcoholic Steatohepatitis
Register for Updates
Impact of Semaglutide on CD34+ EPC and Fat Derived MSC
NCT04126603
Completed
The Investigator is trying to ascertain whether an FDA approved medication of T2DM, Semaglutide, can improve the number, function and gene expression of subjects CD34+ endothelial progenitor cells. EPCs are the source of cells protecting the inner lining of blood vessels and improving their survivability will improve cardiovascular outcome as high glucose environment of diabetes are toxic to these EPC Cells. Improve mitochondrial metabolism of Mesenchymal Stem Cell from subcutaneous fatty tissu... Read More
Gender:
ALL
Ages:
Between 20 years and 90 years
Trial Updated:
04/24/2024
Locations: The GW Medical Faculty Associates, Washington, District of Columbia +1 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
NCT06222437
Not Yet Recruiting
The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
03/26/2024
Locations: Clinical Research Institute at Methodist Health System, Dallas, Texas
Conditions: Polycystic Ovary Syndrome
Register for Updates
Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
NCT06083675
Withdrawn
This study compares the medicines semaglutide with empagliflozin or metformin in people with newly diagnosed type 2 diabetes. This study will look mainly at how well participant's blood sugar and body weight are controlled when they are taking the study medicines. Participants will either get semaglutide tablets, empagliflozin tablets or metformin tablets. Which treatment participants will get is decided by chance. Currently, doses of 3 milligram (mg), 7 mg and 14 mg semaglutide tablets (Rybelsu... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
02/23/2024
Locations: Hillcrest Family Health Center, Waco, Texas +100 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
NCT04741074
Terminated
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or dialysis-dependent end-stage kidney disease (ESKD) on patients' eligibility for kidney transplantation at the end of 9 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Geisinger Medical Center, Danville, Pennsylvania +1 locations
Conditions: CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
Register for Updates
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
NCT03919929
Active Not Recruiting
Girls with obesity and polycystic ovarian syndrome will receive either glucagon like peptide-1 receptor agonist therapy or a dietary intervention for 12 weeks to decrease the metabolic syndrome, in particular to lower hepatic fat and improve insulin sensitivity.
Gender:
FEMALE
Ages:
Between 12 years and 21 years
Trial Updated:
01/25/2024
Locations: University of Colorado Anshutz Medical Campus/Children's Hospital Colorado, Aurora, Colorado
Conditions: PCOS, Adolescent Obesity, NAFLD
Register for Updates
A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
NCT04102189
Completed
This study will look at the change in teenagers' body weight from the start to the end of the study. This is to compare the effect on body weight in teenagers taking semaglutide (a new medicine) and teenagers taking "dummy" medicine. The teenagers in the study and their parents will also have talks with study staff about healthy food choices, how to be more physically active and what they can do to help the teenagers lose weight. The teenagers will either get semaglutide or "dummy" medicine - wh... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/29/2023
Locations: Novo Nordisk Investigational Site, Meridian, Idaho +36 locations
Conditions: Overweight, Obesity
Register for Updates
Treatment of GLP-1 for Diabetic Bariatric Patients
NCT04624672
Terminated
This study is for patients that are diabetic, and require insulin for glycemic control, and going through the bariatric surgery process. This is a prospective study that is trying to determine if the introduction of a semaglutide increases the remission rates of diabetes post-operatively.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/31/2023
Locations: Geisinger Medical Center, Danville, Pennsylvania
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
NCT04944992
Completed
The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat reduction in participants with NAFLD. The primary hypotheses are that efinopegdutide is superior to semaglutide, or that efinopegdutide is superior to semaglutide by at least 10% with respect to mean relative reduction from baseline in liver fat content (LFC) after 24 weeks.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/25/2023
Locations: Catalina Research Institute, LLC ( Site 1939), Montclair, California +68 locations
Conditions: Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Register for Updates
Semaglutide Treatment On Coronary Progression
NCT03985384
Completed
The purpose of this research study is to see the effect of the diabetes medicine Semaglutide on a condition called atherosclerosis. Atherosclerosis is a narrowing, blockage, or hardening of the arteries due to a build up of calcium. This study will look specifically at the arteries involving the heart.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
10/03/2023
Locations: Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, California
Conditions: Type 2 Diabetes, Coronary Artery Disease
Register for Updates
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
NCT06005012
Recruiting
Conduct a community intervention study that will 1) validate a screening approach to identify patients at risk for advanced NAFLD in the obese or T2DM population, and 2) test whether semaglutide treatment is effective for the management of significant fibrosis due to NAFLD in high-risk patients.
Gender:
ALL
Ages:
Between 40 years and 79 years
Trial Updated:
09/01/2023
Locations: University of California, San Diego, La Jolla, California
Conditions: Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
Register for Updates